Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: Toxicity, pharmacokinetics, and biological effects

Clinical Cancer Research

Volumn 2, Issue 7, 1996, Pages 1115-1122

  Lorenz, Joachim ^a   Wilhelm, Kai ^b   Kessler, Mathias ^a   Peschel, Christian ^a   Schwulera, Udo ^c   Lissner, Reinhold ^c   Struff, Wilhelm G ^c   Huland, Edith ^d   Huber, Christoph ^a   Aulitzky, Walter E ^a,e  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c BIOTEST AG   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INHALATIONAL DRUG ADMINISTRATION; LUNG CANCER; LUNG LAVAGE; MALAISE; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VITAL CAPACITY;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; AGED; FEMALE; HUMANS; INTERLEUKIN-2; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 8944234343     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Smith, K. A. Interleukin 2: inception, impact and implications. Science (Washington DC), 240: 1169-1174, 1988.
2. Rosenberg, S. A., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., and White, D. E. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus mterleukin 2. J. Am. Med. Assoc., 271. 907-913, 1994.
3. Maas, R. A., Dullens, H. J. F., and Den Otter, W. Interleukin 2 in cancer treatment: disappointing or still promising. Cancer Immunol. Immunother., 36: 141-148, 1993.
4. Lee, R. E , Lotze, M. T., Skibber, J M., Tucker, E., Bonow, R. O., Ognibene, F. P., Carraquillo, J. A., Shelhamer, J. H., Parillo, J. E., and Rosenberg, S. A. Cardiorespiratory effects of immunotherapy with interleukin 2. J. Clin. Oncol., 7: 7-13, 1989.
5. Lorenz, J., Muller-Quernheim, J., Castillo-Hofer, C., Doboszynska, A., and Ferlinz, R. Assessment of local cellular immunity in lung cancer by bronchoalveolar lavage. Klin. Wochenschr., 68. 728-734, 1990.
6. Mier, J. W , Vachino, G. van der Meer, J. W., Numerof, R. P., Adams, S., Cannon, J. G., Bernheim, H. A., Atkins, M. B., Parkinson, D. R., and Dinarello, C. A. Induction of circulating TNF alpha as the mechanism for the febrile response to interleukin 2 in cancer patients. J. Clin. Immunol , 8: 426-431, 1988.
7. Gemlo, B. T., Palladino, M., Jaffe, H. S., Espevik, T P., and Rayner, A. A. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res., 48: 5864-5870 1988.
8. Steis, R. G., Urba, W. J., VanderMolen, L. A., Bookman, M. A., Smith, J. W., Clark, J. W., Miller, R. L., Crum, E. D., Beckner, S. D., McKnight, J. E., Ozols, R. F., Stevenson, H. C., Young, R. C., and Longo, D. L. Intrapentoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J. Clin Oncol., 8: 1618-1629, 1990.
9. Stewart, J. A., Belinson, J. L., Moore, A. L., Donghi, J. A., Grant, B. W., Haugh, L. D., Roberts, J. D., Albertini, R. J., and Branda, R. F Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine activated killer cells in patients with ovarian cancer. Cancer Res., 50: 6302-6310, 1990.
10. Pizza, G., Severini, G., Menniti, D., De Vinci, C., and Corrado, F. Tumor regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Int. J. Cancer, 62: 359-363, 1984.
11. Astoul, P., Bertault-Peres, P., Durand, A., Catalin, J., Vignal, F., and Boutin, C. Pharmacokinetics of intrapleural recombinant interleukin 2 in immunotherapy for malignant pleural effusion. Cancer (Phila.), 73: 308-313, 1994.
12. Huland, E., and Huland, H. Local continuous high-dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res., 49: 5469-5474, 1989.
13. Hubbard, R. C., Brantly, M. L., Sellers, S. E., Mitchell, M. E., and Crystal, R. G. Antineutrophil elastase defenses of the lower respiratory tract in alpha 1 antitrypsin deficiency directly augmented by an aerosol alpha 1 antitrypsin. Ann. Intern. Med., 111: 206-212, 1989.
14. Kinnula, V., Mattson, K., and Cantell, K. Pharmacokinetics and toxicity of inhaled human interferon alpha in patients with lung cancer. J. Interferon Res., 9. 419-423, 1989.
15. Jaffe, H. A., Buhl, R., Mastrangeli, A., Holroyd, K. J., Saltini, C., Czerski, D., Jaffe, H S., Kramer, S , Sherwin, S., and Crystal, R. Organ specific cytokine therapy: local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon gamma to human lung. J. Clin. Invest., 88: 297-302, 1991.
16. Van Zandwijk, N., Jassem, E., Dubbelmann, R., Braat, P., and Rumke, P Aerosol application of interferon alpha in the treatment of bronchioloalveolar carcinoma. Eur. J. Cancer, 26: 738-740, 1990.
17. Hubbard, R. C., McElvany, N. G., Birrer, P., Shak, S., Robinson, W. W., Jolley, C., Wu, M., Chernick, M. S., and Crystal, R. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N. Engl. J. Med., 326: 812-815, 1992.
18. Huland, E., Heinzer, H., and Huland, H. Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment. J. Cancer Res. Clin. Oncol., 120: 221-228, 1994.
19. Long, J. P., Anglard, P., Gnarra, J. R., Walther, M. M., Merino, M. J., Liu, S., Lerman, M. I., Zbar, B., and Linehan, W. M. The use of molecular genetic analysis in the diagnosis of renal cell carcinoma. World J. Urol., 12: 69-73, 1994.
20. Aulitzky, W. E., Schuler, M., Peschel, C., and Huber, C. Interleukins: clinical pharmacology and therapeutic use. Drugs, 48: 667-677, 1994.
21. Hladik, F., Tratkiewicz, J. A., Tilg, H , Vogel, W , Schwulera, U., Krönke, M., Aulitzky, W. E., and Huber, C. Biological activity of low dosage IL-2 treatment in vivo: molecular assessment of cytokine network interaction. J. Immunol., 153: 1449-1454, 1994.
22. Whittington, R., and Faulds, D. Interleukin 2: a review of its pharmacological properties and therapeutic use in patients with cancer. Drugs, 46: 446-514, 1993.
23. Minasian, L M , Motzer, R. J., Gluck, L., Mazumdar, M., Vlamis, V., and Krown, S. E. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin. Oncol., 11: 1368-1375, 1993.
24. Aulitzky, W , Gastl, G., Aulitzky, W. E., Herold, M., Kemmler, J., Mull, B., Frick, J., and Huber, C. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon gamma. J Clin. Oncol., 7: 1875-1884, 1989.
25. Picker, L. J., Martin, R. J., Trumble, A., Newman, L. S., Collins, P. A., Bergstresser, P R., and Leung, D. Y. Differential expression of lymphocyte homing receptors by human memory/effector T cells in pulmonary versus cutaneous immune effector sites. Eur J. Immunol., 24: 1269-1277, 1994.
26. Mobley, J. L., Rigby, S. M., and Dailey, M. O. Regulation of adhesion molecule expression by CD8 T cells in vivo. II. Expression of L-selectin (CD62L) by memory cytolytic T cells responding to minor histocompatibility antigens. J. Immunol., 153: 5443-5452, 1994.
27. Ruff, M., Henne, C., Barth, T., Rinaldi, N., Strater, J., Schwanz Albiez, R, and Moller, P. PMA-activation of peripheral blood and tonsillar B lymphocytes induces large adhesive cells reminiscent of large extrafollicular (monocytoid) B cells. Virchows Arch., 424: 195-204, 1994.
28. Hermann, G. G., Geertsen, P. F von der Maase, H., and Zeuthen, J. Interleukin-2 dose, blood monocyte and CD25 + lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma. Cancer Immunol. Immunother., 34: 111-114, 1991.
29. Salvo, G , Samoggia, P., Masciulli, R , Boccoli, G., Allavena, P., Mariani, G., Bullo, A., Montesoro, E., Bulgarini, D., Carlini, P., et al. Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: role of cell adhesion to endothelium. Eur. J. Cancer. 28A: 818-825, 1992.